Could a simple meal change ease drug side effects for kids with rare tumor disorder?
NCT ID NCT05101148
Summary
This study is testing whether taking the approved drug selumetinib with a low-fat meal, instead of on an empty stomach, can reduce stomach-related side effects like nausea and diarrhea in teenagers with neurofibromatosis type 1 (NF1) and inoperable tumors. Researchers will measure how much of the drug gets into the body with and without food to ensure it still works effectively. The goal is to find a dosing method that is easier to tolerate while controlling tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
Akron, Ohio, 44308, United States
-
Research Site
Bydgoszcz, 85-094, Poland
-
Research Site
Gdansk, 80-952, Poland
-
Research Site
Warsaw, 02-091, Poland
-
Research Site
Moscow, 119620, Russia
-
Research Site
Moscow, 125412, Russia
-
Research Site
Barcelona, 08950, Spain
-
Research Site
Madrid, 28009, Spain
Conditions
Explore the condition pages connected to this study.